Enap-H tablets

Ülke: Ermenistan

Dil: İngilizce

Kaynak: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Aktif bileşen:

enalapril (enalapril maleate), hydrochlorothiazide

Mevcut itibaren:

KRKA d.d.

ATC kodu:

C09BA02

INN (International Adı):

enalapril (enalapril maleate), hydrochlorothiazide

Doz:

10mg+ 25mg

Farmasötik formu:

tablets

Paketteki üniteler:

(20/2x10/) in blister

Reçete türü:

Prescription

Yetkilendirme durumu:

Registered

Yetkilendirme tarihi:

2022-02-11

Ürün özellikleri

PI_Text005187_1
– Updated:
Page 1 of 18
1.
NAME OF THE MEDICINAL PRODUCT
Enap
®
-H 10 mg/25 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each Enap-H 10 mg/25 mg tablet contains 10 mg enalapril maleate, which
is equivalent to 7.64 mg
enalapril, and 25 mg hydrochlorothiazide.
Excipients:
lactose
114.02 mg
quinolone
yellow (E104)
0.06 mg
sodium
5.1 mg
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablets.
Enap-H 10 mg/25 mg tablets: yellow, round, flat, scored on one side
with beveled edges.
The score
line is not intended for breaking the tablet.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Arterial hypertension (patients for whom the combination therapy is
prescribed).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
The drug is intended for oral treatment.
The dosage of the drug is based primarily on the experience with its
active substance enalapril
maleate.
The usual dose is one tablet once daily. If required, the dose may be
increase to two tablets once daily.
For most patients, 20 mg (exceptionally 40 mg) enalapril maleate or 50
mg hydrochlorothiazide a day
is sufficient; therefore, not more than two Enap-H 10 mg/25 mg tablets
a day are recommended. If no
satisfactory response is achieved, addition of a second drug or
changed therapy is recommended (see
sections 4.3, 4.4, 4.5 and 5.1).
_Prior diuretic therapy_
Symptomatic hypotension may occur following the initial dose of the
drug; this is more likely in
patients who are volume and/or salt depleted as a result of prior
diuretic therapy. The diuretic therapy
should be discontinued for 2-3 days prior to initiation of therapy
with Enap-H 10 mg/25 mg.
_Dosage in renal insufficiency_
Thiazide diuretics may not be appropriate for patients with renal
impairment. They are ineffective in
patients with creatinine clearance values of 0.5 ml/s or less (i.e.
moderate and severe renal
insufficiency).
CONFIDENTIAL
Enap-H 10 mg/25 mg tablet, Enap-HL 10 mg/12.5 mg
tablet
VOL: 1; P: 44 / 792
PI_Text005187_1
– Updated:
Page 2 of 18
In pat